CPP2021-009092
Financiado
Desarrollo de un Producto de Investigación para Terapia Celular Adoptiva, opTcel...
Desarrollo de un Producto de Investigación para Terapia Celular Adoptiva, opTcells para Pacientes con Cáncer Gastrointestinal
Immunotherapy should be considered as one the most revolutionary therapy and the last finding after the development of chemotherapy and targeted therapies. Advances in the understanding of cancer immunobiology and the critical rol...
Immunotherapy should be considered as one the most revolutionary therapy and the last finding after the development of chemotherapy and targeted therapies. Advances in the understanding of cancer immunobiology and the critical role of the tumor microenvironment in facilitating immune escape and disease growth have opened a new horizon in cancer therapeutics.The development of immunotherapeutic strategies to reverse immune paralysis, expand tumor specific effector cells, and create immune memory responses to prevent disease recurrence has begun to yield stunning clinical results. Applicability of this approach to oncological patients suffering from gastrointestinal disease, could be a paradigm shift in their treatment and in providing a highly innovative and promising therapy to potentially prevent disease recurrence in this highly lethal disease. Currently, immunotherapy is widely spread in oncology research and several immune-oncology strategies have been developed and consolidate for melanoma, lung and kidneys cancer treatment.One of the current strategies in immunotherapy is the so-called adoptive cell therapy (ACT). In general terms, this approach is based on using the patient own immune cells to attack cancer. By and large, this approach is based on the use of the patient own immune cells to fight his illness. The application of this innovative and promising approach to gastrointestinal cancer patients could provide a revolution in their treatment and potentially prevent the recurrence of these highly fatal diseases.Over the years, the most used approach has been the harvesting, stimulation and administration of tumor infiltrating lymphocytes (TIL). This approach was successful in patients with malignant melanoma and kidney cancer because these tumors contain high levels of TIL but cannot be used for other cancers, such as gastrointestinals, in which TILs are rare. Its important to bear in mind that gastrointestinal oncological diseases present several peculiarities from the immunology point of view. Intratumoral effector T cells are quite scarce in digestive system unlike other solid tumors, while there is a massive infiltration by immunosuppressive leukocytes, also known as Tregs. On the other hand, the ras oncogene drives an inflammatory response that advantage tumor microenvironment. Finally, the desmoplastic reaction, typical for pancreatic cancer, stimulate angiogenesis and prevent an effective response. Respect to synthetic vaccines, only those drugs which included the RAS peptide alone or in combination with Gemcitabine have shown some clinical effect, in pancreatic cancer. Autologous dendritic cell vaccines have not achieved the expected results. Not even the results of therapies with checkpoint inhibitors have achieved encouraging results, and only two of these therapies have demonstrate some clinical benefit, so far.Several studies describing the TILs isolation, expansion and selection procedures have already been published in gastrointestinal cancers. However, due to the low lymphocyte content in these types of tumors, this approach would only be possible in patients with localized and resectable disease (low percentage of cases). This approach is currently being carried out in clinical, although, in most cases, sample shortage or even absence of lymphocytes could make this therapeutical approach impossible
ver más
01/01/2021
Líder desconocido
110K€
Línea de financiación: concedida
El organismo AGENCIA ESTATAL DE INVESTIGACIÓN notifico la concesión del proyecto el día 2021-01-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
RETOS COLABORACION 21:
Proyectos en colaboración público-privada 2021
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
110K€
Líder del proyecto
Líder desconocido